Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.58 |
| ▸ | MAOB | P27338 | 11/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756894 | 1.00 | MAOA (0.58) | MAOAMAOBKDM4EHTTMAPK14 | |
| SCHEMBL115638 | 0.96 | MAOA (0.58) | MAOAMAOBKDM4EHTTPRKCI | |
| SCHEMBL27323916 | 0.92 | MAOA (0.51) | MAOAMAOBKDM4EHTTMAPK14 | |
| Sulfuric Acid SCHEMBL28143763 | 0.90 | MAOA (0.54) | MAOAMAOBKDM4EHTTMAPK14 | |
| SCHEMBL268592 | 0.89 | KDM4E (0.56) | MAOBKDM4EHTTMETAP1PRNP | |
| SCHEMBL7510392 | 0.88 | METAP1 (0.54) | MAOAMAOBKDM4EHTTMETAP1 | |
| Water SCHEMBL28454486 | 0.87 | KDM4E (0.54) | MAOBKDM4EHTTMETAP1PRNP | |
| SCHEMBL5146484 | 0.86 | MAOB (0.58) | MAOAMAOBKDM4EHTTMAPK14 | |
| SCHEMBL3857144 | 0.84 | MAOA (0.81) | MAOAMAOB | |
| Di(Hydroxyethyl)Ether SCHEMBL28140046 | 0.84 | MAOB (0.51) | MAOAMAOBPRKCIHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-07 | — | — | US | disclosed |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2025-12-04 | — | — | US | disclosed |
| EP-4630403-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-10-15 | — | — | EP | disclosed |
| US-20250262186-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-21 | — | — | US | disclosed |
| US-20250250261-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-07 | — | — | US | disclosed |
| US-20250248970-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-07 | — | — | US | disclosed |
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| EP-4508032-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| EP-4508031-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| EP-4508033-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6225330-B1 | Selective NPY (Y5) antagonists (tricyclics) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6218376-B1 | FOR TREATING INFLAMMATORY DISEASES | ASTRAZENECA UK LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |
| EP-1042320-A1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-10-11 | — | — | EP | disclosed |
| US-6130228-A | Polycyclic compounds | UNIVERSITY OF STRATHCLYDE (GB) | 2000-10-10 | — | — | US | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000008001-A1 | SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999026944-A1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | ASTRAZENEKA UK LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
| EP-0877735-A1 | POLYCYCLIC COMPOUNDS | University of Strathclyde (GB) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997019929-A1 | POLYCYCLIC COMPOUNDS | THE UNIVERSITY OF STRATHCLYDE (GB) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | CYP19A1, ESR1, ESR2 | MAOA 421/4885MAOB 397/4885KDM4E 1277/4885 |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | FSHR, CYP19A1, GPER1 | MAOA 901/4885MAOB 941/4885KDM4E 1708/4885 |
| US-20250250261-A1 | NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | FSHR, GPER1, ESRRA | MAOA 1816/4885MAOB 1407/4885KDM4E 720/4885 |
| US-20250262186-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | FSHR, CYP19A1, GPER1 | MAOA 855/4885MAOB 658/4885KDM4E 685/4885 |
| US-20250248970-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | FSHR, ESRRA, GPER1 | MAOA 942/4885MAOB 870/4885KDM4E 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.